Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Lebrikizumab Autoinjector vs Pre-Filled Syringe in Healthy Participants
NCT04840901Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2021
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lebrikizumab in atopic dermatitis (AD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration of Lebrikizumab at Day 99, Area Under the Concentration Versus Time Curve From Time Zero to Infinity at Day 99 and 1 more. Started Jun 2021; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04840901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840901.